The corticosteroids segment accounts for a significant revenue share in the global market. Corticosteroids are a medication that can reduce inflammation and slow muscle degeneration in patients with limb-girdle muscular dystrophy (LGMD) . Several factors drive the growth of the corticosteroids segment in the global LGMD treatment market. Corticosteroids have been shown to be effective in slowing the progression of LGMD in some patients, leading to their widespread use as a standard of care in many countries. Prednisone and deflazacort (Emflaza) are corticosteroids commonly used in the treatment of limb-girdle muscular dystrophy (LGMD). These medications work by reducing inflammation and slowing the progression of muscle degeneration in patients with LGMD. They have been shown to improve some patients' muscle strength, function, and quality of life.
The prevalence of LGMD is increasing globally, driving demand for effective treatment options, including corticosteroids. Corticosteroids are relatively inexpensive compared to other treatment options, which can make them an attractive option for patients and healthcare providers.
ANP Price at posting:
7.5¢ Sentiment: Buy Disclosure: Held
